作者
Brianna Tramelli,Dereck Shi,Zwelithini Tunyiswa,Thomas E Serena
摘要
Background: Diabetic foot ulcers (DFUs) are associated with impaired healing, infection, hospitalization, amputation, mortality, and substantial health care costs. Building on prior randomized and observational evidence with ON101, PREPUP ONE will evaluate early wound-bed optimization with ON101 versus clostridial collagenase ointment using Week 4 percent area reduction (PAR). Methods: PREPUP ONE is a prospective, multicenter, active-comparator, parallel-group randomized trial embedded in an adaptive hybrid master protocol. Approximately 100 adults with DFUs will be randomized 1:1 at up to 15 SerenaGroup research or affiliated centers to NWBOT + standard of care (SOC) or clostridial collagenase ointment (CCO) + SOC. Study products will be applied at treatment visit 1 (TV-1) through to TV-4. In addition, CCO will be applied once daily by participants at home, whereas NWBOT will be provider-applied at a frequency consistent with the applicable Instructions for Use and the healthcare provider’s instructions during the 4-week treatment period. SOC includes wound cleansing, sharp debridement, moisture-balancing dressings, and offloading. Although treatment allocation cannot be masked, wound-area assessments will use protocol-specified digital imaging and physical examination and will be reviewed by an independent blinded adjudication panel using de-identified digital images. The primary endpoint is Week 4 PAR measured by protocol-specified digital planimetry. The definitive frequentist analysis will use analysis of covariance adjusted for log baseline wound area and site or pooled site, with a proposed 10-PAR-point non-inferiority margin. A complementary Bayesian, estimation-only hurdle-gamma analysis of weekly wound area will derive Week 4 PAR from posterior model estimates. Participants will be followed for harms and selected patient-reported outcomes through Week 16. Supportive, nonrandomized comparisons with synthetic SOC, synthetic topical collagen, and matched topical hydrogel cohorts are planned. Results: Results will be reported in prespecified interim and final analyses after the applicable data cuts, quality-control procedures, and source- document reconciliation are complete. Conclusions: PREPUP ONE establishes a multicenter, randomized active-comparator framework to evaluate early wound response within a standardized US DFU care pathway. By integrating objective Week 4 PAR assessment with subsequent clinical and patient-reported outcomes, the trial is designed to generate clinically interpretable evidence on early wound improvement and its association with the subsequent clinical course and selected downstream clinical outcomes of DFU management.